Study to Determine the Safety and Effectiveness of Dupilumab (REGN668/SAR231893) for Treatment of Atopic Dermatitis (AD)

This study has been completed.
Information provided by (Responsible Party):
Regeneron Pharmaceuticals Identifier:
First received: November 1, 2013
Last updated: April 2, 2015
Last verified: April 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2015
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: April 2, 2015